UBS Group
LGND icon

UBS Group’s Ligand Pharmaceuticals LGND Stock Holding History

UBS Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-122,309
Closed -$11.6M – 9616
2021
Q1 		$11.6M Buy
122,309
+68,769
+128% +$6.5M ﹤0.01% 1823
2020
Q4 		$3.32M Buy
+53,540
New +$3.05M ﹤0.01% 2886

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

UBS Group's LGND Position: Q1 2026 in Review

UBS Group reduced its Ligand Pharmaceuticals (LGND) stake by 27% in Q1 2026, selling an estimated $7.61M and leaving 104,580 shares worth $20.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2530.

UBS Group first reported a position in LGND in Q4 2014 and has held it in 46 quarters since. The position peaked at $27M in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • UBS Group held 104,580 shares of Ligand Pharmaceuticals worth $20.9M as of Q1 2026.
  • UBS Group sold 38,487 Ligand Pharmaceuticals shares in Q1 2026, an estimated $7.61M.
  • Ligand Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2530 holding.
  • UBS Group first reported a position in Ligand Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Ligand Pharmaceuticals position peaked at $27M in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.